Related Experiment Video
Updated: Aug 14, 2026
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
Published on: March 6, 2015
Lymph-Targeted Resveratrol-NLCs Improve Oral Bioavailability: Validation via Rat Mesenteric Lymph Collection System
Xiaorui Zhang1,2, Wenli Shi1, Xinlin Yang1
1Fujian Key Laboratory of Traditional Chinese Veterinary Medicine and Animal Health, College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
Animals : an Open Access Journal From MDPI
|August 13, 2026
Summary
Resveratrol-loaded nanostructured lipid carriers (RES-NLCs) enhance oral absorption by promoting intestinal lymphatic uptake. This delivery system significantly boosts resveratrol bioavailability and shows potential for hydrophobic drugs.
Area of Science:
- Pharmacology
- Drug Delivery
- Nanotechnology
Background:
- Resveratrol (RES) exhibits poor aqueous solubility and high first-pass metabolism, leading to low oral bioavailability.
- Existing evidence for RES-NLCs' lymphatic transport is largely inferential, lacking direct experimental validation.
Purpose of the Study:
- To investigate the intestinal lymphatic transport mechanism of RES-NLCs.
- To evaluate the pharmacokinetic profile and oral bioavailability enhancement of RES-NLCs.
- To assess the safety of RES-NLCs through a repeated-dose toxicity study.
Main Methods:
- Preparation and characterization of RES-NLCs.
- Pharmacokinetic and lymphatic transport evaluation using a rat mesenteric lymph duct model.
- 28-day repeated-dose toxicity study in ICR mice.
Main Results:
- RES-NLCs increased Cmax by 2.3-fold, improved relative bioavailability by 7-fold, and achieved 176% absolute bioavailability compared to RES-Sol.
- Direct evidence confirmed RES-NLCs are absorbed via the intestinal lymphatic pathway.
- Toxicity studies showed no mortality; mild changes in liver/spleen coefficients and hematological parameters were observed, but no significant organ damage or structural abnormalities.
Conclusions:
- RES-NLCs effectively enhance oral bioavailability by promoting intestinal lymphatic uptake.
- The RES-NLCs system demonstrates potential as an efficient delivery platform for poorly soluble hydrophobic drugs.
- RES-NLCs exhibit a favorable safety profile at the tested dose, warranting further investigation.
